Finch Therapeutics Group Inc

$2.74 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Finch Therapeutics Group Inc

Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company. The Company leveraging Human-First Discovery platform to develop a class of orally administered biological drugs. It is developing therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The Company’s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection (CDI). It is also advancing CP101 for the treatment of chronic hepatitis B virus (HBV) Its product pipeline includes FIN-524, FIN-525, and FIN-211.

Stock Analysis

last close $2.74
1-mo return 35%
3-mo return -47.2%
avg daily vol. 155.14T
52-week high 17.39
52-week low 1.71
market cap. $125M
forward pe -
annual div. -
roe -32.8%
ltg forecast -
dividend yield -
annual rev. $15M
inst own. 22.3%
baraka

Subscribe now for daily local and international financial news

Subscribe